Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s fastest-growing Contract Research, Development, and Manufacturing Organizations (CRDMO), has announced the groundbreaking of its new CMC Process R&D Center at the company’s integrated R&D campus in Hyderabad. The upcoming facility, scheduled for completion by September 2026, will significantly enhance Sai Life’s R&D infrastructure by doubling its existing Process R&D capacity and introducing advanced capabilities in peptide development, oligo intermediates and linkers, formulation development, and early-phase clinical supplies.
Spread across 100,000 sq. ft. and five floors, the new center is designed as a green building with state-of-the-art laboratories, including a centralized analytical lab, peptide and oligo intermediate facilities, a kilo lab for early clinical manufacturing, and NCE formulation development capabilities. It will operate under containment levels down to OEL 4 (1 µg/m³), ensuring high safety and compliance standards.
The CMC Process R&D Center represents a strategic investment in innovation, scale, and sustainability. It will support both Full-Time Equivalent (FTE) and Dedicated Project Capacity (DPC) models, enabling Sai Life Sciences to collaborate flexibly with global innovators across the entire drug development lifecycle—from early-stage research to late-stage CMC programs. This initiative aligns with the company’s broader capital expenditure plans, driven by strong global demand for scalable, high-quality, and partnership-driven drug development solutions.
